Pharma in her DNA, Wockhardt scion ready for deep dive in the US
Published on: June 10, 2026, 12:41 a.m. | Source: The Economic Times
Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacterial infections and is a significant bet for the company. Zaynich's US approval marks a major breakthrough after decades without new antibiotics. Zahabiya is focused on hospital penetration, physician advocacy, and demonstrating economic value to healthcare systems.
